कंपनी का अवलोकन
Stryker Corporation operates as a leading medical technology enterprise serving markets across the United States and internationally through its MedSurg and Neurotechnology, Orthopaedics, and other segments. This organization functions within the Healthcare sector, specifically the Medical Devices industry, providing surgical equipment, patient safety technologies, and navigational tools that are critical for modern clinical operations. The company demonstrates substantial scale with a total market capitalization of $130.22B, annual revenue of $25.12B, and a workforce comprising 56,000 employees. These valuation and revenue figures indicate that Stryker holds a dominant position within the global medical device landscape, reflecting significant market share and established brand recognition among healthcare providers and distributors.
वित्तीय स्वास्थ्य
The company reported a trailing twelve-month revenue of $25.12B, net income of $3.25B, and EBITDA of $6.95B, highlighting a distinct gap between top-line sales and bottom-line profit that reveals a significant cost structure involving research, development, and operating expenses. The firm generated free cash flow of $4.17B, which provides robust financial flexibility to fund capital expenditures, manage working capital, and potentially pursue strategic acquisitions without relying on external financing. Profitability analysis shows a gross margin of 65.0%, indicating high pricing power and efficient production; an operating margin of 27.2% demonstrates effective control over overhead and administrative costs; and a profit margin of 12.9% reflects the final earnings available to shareholders after all expenses. On the balance sheet, cash holdings of $4.10B are substantially lower than total debt of $16.36B, while a debt-to-equity ratio of 72.97% suggests a leveraged capital structure typical for capital-intensive manufacturing industries. Liquidity is supported by a current ratio of 1.89, indicating that current assets are nearly double current liabilities, which ensures adequate coverage for short-term obligations. Return on equity stands at 15.1% and return on assets is 7.9%, metrics that reveal management's effectiveness in generating returns relative to the shareholders' equity and the total asset base utilized to drive operations.
मूल्यांकन आकलन
Valuation metrics show a trailing P/E ratio of 40.48 and a forward P/E of 20.31, where the significant difference implies that the market expects earnings growth that will substantially narrow the multiple over the coming fiscal periods. The price-to-book ratio is 5.80, indicating that the stock trades at a substantial market premium over its tangible book value, reflecting intangible assets like intellectual property and brand strength. Alternative valuation measures include a price-to-sales ratio of 5.18 and an EV/EBITDA of 20.49, which suggest the company is valued highly relative to its sales and operating earnings, consistent with high-growth medical device peers. The stock price has traded between a 52-week low of $319.32 and a 52-week high of $404.87, placing the current valuation in a range that reflects recent market volatility and investor sentiment regarding the healthcare sector. The beta of 0.93 indicates that the stock's price volatility is slightly lower than the broader market, suggesting a relatively stable correlation with general market movements during periods of economic fluctuation.
Growth & Income
Growth dynamics are characterized by a revenue growth rate of 11.4% and an earnings growth rate of 55.9% year-over-year, demonstrating that earnings are expanding at a much faster pace than revenue, which often signals improved operational leverage or favorable product mix shifts. As a dividend payer, the company offers a yield of 1.0% with a payout ratio of 40.5%, indicating that the dividend is sustainable as it consumes less than half of the annual net income. The low payout ratio allows the firm to retain a significant portion of earnings for reinvestment into R&D and manufacturing capacity rather than distributing them entirely to shareholders. Overall, the growth and income profile presents a hybrid characteristic of a mature market leader that delivers steady cash returns while maintaining aggressive earnings expansion relative to sales growth.